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Acute promyelocytic leukemia (APL) is characterized by PML-RARα, a fusion protein 
resulting from a chromosomal translocation between the promyelocytic leukemia (PML) gene 
and retinoic acid receptor α (RARα) gene. PML-RARα was shown to promote misfolding and 
accumulation of nuclear receptor co-repressor (N-CoR) in the endoplasmic reticulum (ER) and 
cause unfolded protein response (UPR)-linked apoptosis. However in APL cells, N-CoR was 
found to be degraded, relieving ER stress and escaping cell death. Previous results also showed 
that autophagy was elevated in APL cells and drug inhibition of autophagy led to a stabilization 
of N-CoR with corresponding decrease in adenosine triphosphate (ATP) levels, suggesting a 
possible function of N-CoR where APL cells may use its degradation through autophagy to 
provide an alternative energy source for cancer cell survival. Here, I report a drug artemisinin as a 
potential therapeutic agent which selectively promotes growth inhibition and apoptosis in APL 
cells. Artemisinin enhanced the degradation of N-CoR, which could be restabilized by treatment 
with a proteasome inhibitor. Levels of autophagic and survival markers, and ATP in APL cells 
also decreased after artemisinin treatment. These findings suggest that artemisinin possibly 
enhances the proteasomal degradation of misfolded N-CoR, thus depriving cancer cells of the 
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Chapter 1: Introduction 
1.1 Leukemia 
Leukemia, a hematological malignancy, is caused by an abnormal increase in 
leukocytes produced in the bone marrow.  It can be categorized as acute or chronic, 
depending on the maturity of cancer cells which affects the progression of disease. 
Acute leukemia is characterized by the rapid expansion of undifferentiated precursor 
cells, while chronic leukemia is characterized by excessive accumulation of mature 
white blood cells. Leukemia is subdivided into lymphoid or myeloid leukemia, 
depending on the lineage of hematopoietic cells affected. Lymphocytic leukemia 
mainly consists of lymphocytes like early B-cells, precursor B-cells and precursor T-
cells. Myeloid leukemia involves myeloid cells like early myeloblasts, myeloblasts, 
promyelocytes, myelocytes and neutrophils, monoblasts and monocytes, 
megakaryoblasts, or erythroid precursors.  
Collectively, there are four main types of leukemia – acute lymphoid leukemia 
(ALL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), and 
chronic myeloid leukemia (CML). ALL is the most common leukemia in children 
while AML and CLL are most common in adults [1]. There are many subtypes of 
AML and the French-American-British (FAB) Cooperation Group’s classification 
system based on morphological features is widely used [2]. A newer and improved 
classification by the World Health Organization (WHO) is also being used. This 
classification incorporates cytogenetic results that links the FAB subtypes to 
associated chromosomal translocations [3].  
Reciprocal translocations between non-homologous chromosomes have been 
implicated in various diseases including leukemia [4]. A common chromosomal 
abnormality is the t(9;22) translocation between the Abl1 and BCR genes, which is the 
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hallmark of CML and ALL. Chromosomal translocations can be grouped into seven 
subtypes – translocations involving the MLL gene (AML), CBF and TEL/ETV6 genes 
(childhood ALL, AML, CML), retinoic acid receptor α (RARα) (AML), E2A gene 
(ALL), tyrosine kinases (CML), nucleoporins (AML) and immunoglobins or T-cell 
receptors (ALL). A comprehensive list of recurring chromosome translocations in 
leukemia can be found in Table 1 in [5]. 
 
1.2 Acute promyelocytic leukemia (APL) 
APL is classified as AML-M3 under the FAB classification system [2]. It 
accounts for about 10-15% of all AML cases in adults [6], with a lower incidence in 
children [7]. APL is characterized by the fusion protein PML-RARα, which is a result 
of a reciprocal translocation between the promyelocytic leukemia (PML) gene on 
chromosome 15 and retinoic acid receptor (RAR) gene on chromosome 17. PML-
RARα can be found in 98% of APL cases [8, 9]. Other rare forms of APL involve the 
fusions of RARα to promyelocytic leukemia zinc finger (PLZF), nucleophosmin 
(NPM), nuclear matrix-associated (NuMA) and signal transducer and activator of 
transcription 5b (STAT5b) [10]. APL associated with these fusion proteins are 
responsive to all-trans retinoic acid (ATRA), with the exception of PLZF-RARα and 
possibly STAT5b-RARα- associated APL, which are ATRA-resistant [11, 12].  
Morphologically, APL is characterized by the arrest of leukemic cells at the 
promyelocytic stage during granulocytic differentiation [13]. According to the FAB, 
there are two main cytological subtypes, the classical hypergranular form and the 
variant microgranular form [2, 14]. The hypergranular form features numerous coarse 
granules in the cytoplasm, where multiple Auer bodies are also commonly found. 
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Leukemic cells of the microgranular form have sparse granules with bilobed nuclei 
[13].  
APL is also characterized by the disintegration of PML oncogenic domains 
(PODs) or nuclear bodies (NBs), which are dot-like structures in the nucleus [15, 16]. 
PODs have been proposed to act as organizing centers for the regulation of several 
important cellular processes like transcription and development [17-19]. Thus the 
disintegration of PODs is hypothesized to be linked to the differentiation arrest of 
APL cells [20].  
 
1.2.1 Role of PML-RARα in APL  
As mentioned earlier, PML-RARα fuses the N-terminus multimerization 
domain of PML to the DNA and ligand-binding domains of RARα [10, 21]. While the 
RARα portion remains constant, different breakpoint cluster regions (bcr1-3) in PML 
give rise to fusion proteins of different lengths. Majority of the APL patients exhibit 
the long PML-RARα resulting from breakage at bcr1. Breakage at bcr2 yields an 
intermediate length of PML and bcr3 yields the shortest PML [10]. Detection of these 
PML-RARα transcripts allows for a sensitive and specific test for the diagnosis of 
APL [22].  
There have been multiple studies on the role of PML-RARα in the 
pathogenesis of APL and PML-RARα has been proposed to act as a dominant 
negative transcription repressor of RA target genes essential for promyelocyte 
differentiation [20]. PML-RARα disrupts the normal functions of both PML and 
RARα. It can form homodimers and also heterodimerizes with PML and RXR 
separately. Unlike wildtype RARα, which requires binding to RXR to bind DNA, 
PML-RARα homodimers can bind to retinoic acid response elements (RAREs) and 
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act as constitutive repressors [10, 23]. Nuclear corepressor complexes containing N-
CoR [24] and silencing mediator of retinoic and thyroid receptors (SMRT) [25], and 
histone methyltransferases [26] are recruited to the promoters of RA target genes, 
resulting in transcriptional repression of genes required for differentiation of 
granulocytes. Pharmacological concentrations of ATRA is needed to dissociate N-
CoR from PML-RARα, an event that destabilizes and promotes the degradation of the 
latter protein [27].  
While normal PML is localized to NBs, it is found to be delocalized to 
microspeckles after forming heterodimers with PML-RARα [15, 16]. PML-RARα 
may also draw other nuclear proteins like RXR and Rb into the microspeckles [16, 
28]. In addition, Daniel et al. found that a large proportion of PML-RARα was 
localized in the cytoplasm instead of the nucleus, strengthening the idea that PML-
RARα could draw critical factors from RAR target genes [10, 29]. There is also a 
gain-of-function of PML-RARα. Through the PML moiety, PML-RARα is able to 
bind to a large variety of de novo target sequences that were previously not efficiently 
recognized by the normal RXR-RARα heterodimers. This leads to the transcriptional 
deregulation of sites recognized by other nuclear receptors controlling processes such 





Figure 1.1. Suggested model of PML-RARα action in APL [10]. 
 
1.2.2 N-CoR and its role in APL 
Nuclear receptor co-repressor (N-CoR) is a 270 kDa protein that was 
discovered with SMRT as interacting partners and mediators of the repressive 
functions of unliganded RAR and thyroid hormone receptor (TR) [31, 32]. Both 
proteins contain nuclear receptor interaction domains (NRIDs), multiple repressor 
domains (RDs) and Swi3/Ada2/N-CoR/TFIIIB (SANT) motifs [31-35]. SANT motifs 
are postulated to act as histone binding modules and RDs may serve as binding 
platforms for the various enzymes like histone deactylases (HDACs) recruited to 
repress gene promoters. Although N-CoR and SMRT are similar, their functions are 




Figure 1.2. The domains of N-CoR. Repression domains (RI, RII, RIII) and SANT 
domains (A and B) are indicated, as are interaction domains for HDACs, nuclear 
receptors (I and II) and other transcription factors [36]. 
 
N-CoR and SMRT can form complexes with many proteins. These proteins 
that were consistently found in a complex with N-CoR/SMRT include HDAC3, 
transducin β-like 1 (TBL1), the TBL1-related protein (TBLR1) and G protein 
pathway suppressor 2 (GPS-2) [37-40]. TBL1, TBLR1 and GPS-2 help to regulate the 
stability and activity of the corepressor complex. TBL1 and TBLR1 mediate the 
proteasome-dependent degradation of N-CoR/SMRT complexes from promoters, to 
allow de-repression of the gene and recruitment of coactivators [41]. One major 
function of N-CoR and SMRT is to repress gene transcription. N-CoR and SMRT 
binds and activates HDAC3 through their deacetylase activating domain (DAD) [42]. 
HDAC3 then mediates the deactylation of lysines on the histone tails of target 
promoters to promote repression [43]. A ‘feed-forward mechanism’ of repression by 
the N-CoR/SMRT complex has been proposed by Yoon et al [40]. Current models 
suggest that the corepressor complex binds acetylated chromatin and deacetylates the 
histone tails. The complex shows an increased binding affinity for the hypoacetylated 
product, thus enhancing gene repression [43]. The N-CoR/SMRT complex can also 
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interact with Ski, Sno and mSin3 to regulate the tumour suppressor Mad-mediated 
transcriptional repression [44]. Together, the N-CoR/SMRT complex and HDAC3 
facilitate transcriptional repression by various transcription factors to regulate 
multiple cellular processes like differentiation, proliferation and apoptosis [36]. They 
also play a role in development, metabolism and inflammation [45]. A list of the 
interacting transcriptional factors and their roles is shown in Table 1.1 [36]. 
 
Table 1.1 Summary of transcription factors interacting with N-CoR and their 
roles in cellular processes 
 
Transcription factor  Role in cellular processes 
POU homeodomain factors 
Pit1 
Development, differentiation of pituitary cells 
Homeobox factor PBX Determiner of cell fate and segment identity 
Bcl-6 Apoptosis  
MAD, MyoD and HES-
related repressor proteins 
(HERPs) 
Suppress proliferation, induce terminal differentiation 
Su(H)/RBP-J/CBF1 Differentiation, proliferation, apoptosis 
 
N-CoR has been implicated in cancers and neuronal diseases. In various 
leukemias like APL and AML, PML-RARα and AML1-ETO fusion proteins bind to 
the N-CoR/SMRT histone deacetylase complex, resulting in gene repression that 
blocks differentiation and allow uncontrolled growth of hematopoietic cells [45]. In 
Huntington’s disease, N-CoR is localized with mSin3 exclusively in the cytoplasm of 
the cortex and caudate, while in the normal brain, both proteins are localized in both 
nucleus and cytoplasm. This suggests that relocalization of N-CoR results in alteration 
of transcription and pathogenesis of disease [46]. Recently, N-CoR has also found to 
be involved in glioblastoma multiforme (GBM). Further, increased nuclear N-CoR 
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expression has been found in severe grades of astrocytomas, where it maintains 
tumour cells in an undifferentiated state [47].  
 
1.2.3 Current knowledge of the role of PML-RARα and N-CoR in APL 
pathogenesis 
As mentioned earlier, N-CoR is involved in the regulation of multiple 
biological processes and is essential for Mad-mediated transcriptional repression, 
which is responsible for the regulation of the growth and maturation of myeloid cells. 
PML-RARα inhibits this Mad- and Rb- mediated transcriptional repression and leads 
to transformation of APL. Deletion of two N-CoR interacting sites in PML-RARα, the 
coiled-coil domain on PML and CoR-box on RAR, prevents this inhibition [48, 49], 
suggesting that PML-RARα may bind aberrantly to N-CoR and lead to a loss of 
function. Natively folded N-CoR normally localizes in the nucleus when associated 
with PML or RAR protein and is also detergent-soluble [50]. However, significant 
levels of PML-RARα are found in the cytoplasm [15] and it is hypothesized that the 
cytoplasmic PML-RARα may bind N-CoR and promote its conformational change, 
causing it to accumulate as insoluble protein aggregates in the endoplasmic reticulum 
(ER) [50].  
Besides leading to a loss of N-CoR function by lifting the repression of self-
renewal genes, there may also be a gain of function of N-CoR. It has been observed in 
APL cells that there are two distinct forms of PML-RARα and N-CoR, which is 
nuclear and cytosolic. Similar to cytosolic PML-RARα engaging the cytosolic form of 
N-CoR, it is likely that nuclear PML-RARα recruits the native N-CoR to turn on the 
expression of RA target genes [20]. The combined deregulation of the two pathways 
eventually contributes to transformation of APL. 
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1.2.4 Current treatment strategies for APL 
APL was first treated in the 1970s with anthracyclins or anthracyclins 
combined with cytarabine (Ara-C). Previous reports have shown that daunorubicin 
and idarubicin used as single agents induced complete remission (CR) in 55-88% of 
patients [51, 52]. The introduction of ATRA, a non-cytotoxic differentiating agent, by 
a Shanghai group in 1998, has led to an improved prognosis of APL with a better 
long-term outcome [53]. CR of up to 90% was observed and the biologic signs of 
coagulopathy also improved. CR was achieved through the differentiation of APL 
blasts to mature granulocytes [54-56]. However, most patients were found to relapse 
with just ATRA treatment alone [54].  
Currently, the standard induction therapy for APL is based on the combination 
of ATRA and chemotherapy [57, 58]. Combining both therapies has been reported to 
reduce the incidence of relapse and allows for a more effective control of ATRA-
induced leukocytosis, thus reducing the incidence and severity of ATRA syndrome 
[54, 57]. ATRA syndrome is a potentially fatal occurrence which can result from 
treatment with ATRA. ATRA degrades PML-RARα, which contributes to remission 
of APL and degradation of PML-RARα occurs via three pathways. First, proteases 
activated by RA-induced differentiation cleave the PML moiety of PML-RARα [27, 
59]. Second, RA-induced transcriptional activation is coupled to proteasome-mediated 
RARα degradation [60] while the third pathway involves degradation through the 
mTOR autophagic pathway [61].  
Arsenic trioxide (ATO) is an effective therapy for relapsed patients who were 
treated with the ATRA/chemotherapy combination therapy. Studies have shown ATO 
to induce CR in 80-90% of relapsed patients [62]. Shen et al. also reported that 
combination therapy of ATRA and ATO was effective in achieving a similar CR rate 
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within a shorter period of time [63]. ATO has a dual mechanism of action where it 
induces differentiation of APL cells at low concentrations and apoptosis at high 
concentrations [57]. Like ATRA, ATO also degrades PML-RARα but via degradation 
of the PML moiety, along with normal PML. It targets PML-RARα and PML into 
nuclear bodies before inducing degradation. There are two mechanisms by which 
nuclear body formation takes place. First, ATO induces the formation of reactive 
oxygen species (ROS) [64], which causes multimerization of PML, targeting to 
nuclear bodies and PML sumoylation by ubiquitin-conjugating enzyme 9 (UBC9) 
[65]. Second, ATO can also bind PML cysteines directly [65, 66], enhancing UBC9 
binding to the PML RING finger and ultimately PML sumoylation [66]. PML 
sumoylation results in the recruitment of the SUMO-dependent ubiquitin ligase and 
RING finger protein 4 (RNF4) to PML nuclear bodies. RNF4 poly-ubiquitylates PML 
and targets it to the proteasome for degradation [67, 68]. Degradation of PML-RARα 
by ATRA and ATO relieves the transcriptional repression by the fusion protein and 
allows for normal regulation of RARα-responsive genes to induce myeloid 
differentiation [69].  
 
1.2.5 Rationale for the need of new therapeutic options 
Although current treatments for APL including ATRA, ATO and 
chemotherapy have proven to be very effective and are able to induce high CR rates, 
there are a few drawbacks which warrant the need to develop new therapeutic agents. 
One factor is the relapse of patients after CR. Relapse occurs in 5-30% of APL 
patients treated with ATRA and chemotherapy. The relapse rate is higher in high-risk 
patients with high white blood cell (WBC) count [52, 62].  
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Another factor to be considered is the side effects of ATRA and ATO 
treatment. ATRA can lead to major blood hyperleukocytosis [70] and the potentially 
fatal differentiation syndrome (DS) (formerly known as ATRA syndrome) [71]. 
Symptoms include dyspnea, unexplained fever, weight gain, peripheral edema, 
unexplained hypotension, acute renal failure or congestive heart failure, and 
particularly if a chest radiograph demonstrates interstitial pulmonary infiltrates or 
pleuropericardial effusion [72]. Occurrence of DS is also associated with an increased 
risk of subsequent relapse. Currently, no significant prognostic markers have been 
found for the prediction for DS [73].In addition to DS, ATO is also associated with 
cardiac arrhythmia [74] and electrolyte abnormalities [54].  
Secondary resistance occurs in all patients treated with ATRA [75]. Hence 
ATRA needs to be used in combination with chemotherapy, and this may subject the 
patients to cardiac toxicity in the long-term [54, 76]. Thus, it is crucial to develop new 
therapeutic agents that specifically target APL cells, reduce relapse rates, and also to 
reduce chemotherapy-associated toxicity.  
 
1.2.6 Artemisinin: a candidate drug for APL 
Artemisinin is a sesquiterpene lactone isolated from the Artemisia annua 
plant. It has been used in Chinese traditional medicine for 2000 years in the treatment 
of fever and malaria [77]. Besides isolation from the plant, artemisinin has also been 
produced from Saccharomyces cerevisiae engineered to produce the artemisinin 
precursor, artemisinic acid [78]. 
Artemisinin and its derivatives are currently recommended by the World 
Health Organization (WHO) for the treatment of Plasmodium falciparum strains of 
malaria which have developed resistance to traditional anti-malarial drugs like 
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chloroquine and sulfadoxine-pyrimethamine [79, 80]. Due to the short half-life of the 
drug, artemisinin derivatives are commonly used in combination with another longer-
acting drug, known as artemisinin-based combination therapy (ACT). Current ACTs 
use the artemisinin derivatives such as artemether, artesunate or dihydroartemisinin. 
These are chemically modified analogues synthesised to improve the bioavailability 
of artemisinin [81].  
In addition to being an effective anti-malarial drug, artemisinin and its 
derivatives have also been found to exhibit anti-cancer properties like arresting the 
growth or inducing apoptosis of cancer cells. The Developmental Therapeutics 
Program of the National Cancer Institute in USA analysed 55 human cancer cell lines 
and showed that artesunate has strong anti-cancer activity against many cancer cell 
lines like leukemia, colon cancer, melanomas, breast, ovarian, prostate, central 
nervous system and renal cancer cell lines [82]. Another artemisinin derivative, 
dihydroartemisinin, has also been shown to inhibit the growth of human ovarian 
cancer cells and sensitise them to carboplatin therapy [83]. There are various 
mechanisms by which artemisinin exert its anti-proliferative effect. It may induce 
apoptosis by activating caspase 3, increasing poly ADP-ribose polymerase (PARP) 
and the Bax/Bcl-2 ratio, and downregulating Mdm2. It can also downregulate the 
transcription of Cdk4 to block cell cycle progression [84].   
 
1.3 ER stress and protein folding 
1.3.1 Protein folding  
Protein folding is a process essential for cellular function. Secreted, 
membrane-bound and organelle-targeted proteins are synthesized and folded in the 
endoplasmic reticulum (ER) [85]. Newly synthesized polypeptide chains are 
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translocated into the ER and begin folding as they are co-translationally modified with 
the addition of disulphide bonds or N-linked glycans [86, 87]. The ER has an 
oxidizing environment containing high amounts of adenosine triphosphate (ATP) and 
Ca2+ for its proper function [85]. Chaperones are key components that regulate 
folding of proteins. They assist in the folding of newly translated proteins, refolding 
of misfolded proteins, prevent aggregation and facilitate proteolytic degradation [88].  
In the ER, three classes of proteins mediate the folding of nascent proteins – 
foldases, molecular chaperones and lectins [89]. Foldases like protein disulphide 
isomerase (PDI) and peptidyl prolyl cis-trans-isomerase (PPI) accelerate the rate-
limiting steps of the folding process by catalyzing the formation of disulphide bonds 
or isomerization of peptide bonds proximal to proline residues respectively [90].  
Common molecular chaperones include GRP78 (also known as BiP) and 
GRP94. GRP78 belongs to the heat shock protein (Hsp) 70 chaperone family. It 
consists of an N-terminal ATPase and a C-terminal substrate binding domain. 
Conformational changes in GRP78 regulate its binding affinity for peptides in an 
ATP-dependent manner. The ATP-bound state allows for peptide binding, which is 
stabilized when ATP is hydrolyzed to ADP. PDI then promotes disulphide reduction 
and rearrangement until proper folding is achieved. Lastly, nucleotide exchange 
factors catalyze the ADP-ATP exchange and the folded protein is released [88, 91].  
Partially folded monoglucosylated N-linked glycans are recognized by the 
lectins, calnexin (CNX) and its soluble homologue calreticulin (CRT) [92]. CNX and 
CRT bind to thiol oxidoreductase ERp57 [93] to facilitate disulphide bond formation 
[94]. Glucosidase II removes the glucose residue and enables the release of 
glycoproteins from the lectins. If folding is not completed, the glycoprotein is 
reglucosylated by UDP-glucose glycoprotein glucosyltransferase (UGGT) and the 
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cycle of binding and release from the lectins can repeat until proper folding is 
achieved [95, 96]. Improperly folded proteins may ultimately be targeted for 
proteasomal degradation by ER degradation-enhancing α-mannosidase-like protein 
(EMEM), which removes the mannose residue [97, 98]. 
ER is the place for de novo folding of proteins and also refolding of misfolded 
proteins. Otherwise, misfolded proteins are translocated in a retrograde fashion to the 
cytosol for refolding by cytosolic Hsp family chaperones or targeted for degradation 
by the 26S proteasome [99]. 
 
1.3.2 The ubiquitin-proteasome proteolytic pathway 
The ubiquitin-proteasome system (UPS) is a major regulatory pathway 
involved in protein degradation. It is responsible for the controlled degradation of 
proteins involved in cellular processes like cell cycle, DNA repair, immune and 
inflammation response as well as response to stress to maintain normal cellular 
homeostasis [100]. Hence, deregulation of the proteosomal pathway results in 
diseases like neurodegenerative diseases and cancers [101]. 
In the ER, misfolded proteins are usually refolded by chaperones. When 
refolding fails, the misfolded proteins are usually degraded by ER proteinasesand 
either directed to the lysosome or transported back to the cytosol for proteosomal 
degradation [102]. Proteins targeted for recognition and degradation by the 26S 
proteasome undergo covalent attachment of multiple ubiquitin molecules. This 
ubiquitination process proceeds in a three-step mechanism. The first step involves the 
ATP-dependent activation of the C-terminal glycine of ubiquitin by E1 (ubiquitin-
activating enzyme) to a thiol ester intermediate. Next, E2 (ubiquitin-conjugating 
enzyme) transfers the ubiquitin molecule from E1 to the ubiquitin-protein ligase, E3-
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bound protein substrate. Lastly, the ubiquitin-tagged proteins are degraded by 
proteases in the 26S proteasome [103]. 
 
1.4 Autophagy 
Autophagy is a catabolic degradation process important for homeostatic 
functions like protein degradation and organelle turnover. It generally plays a house-
keeping role by degrading misfolded or aggregated proteins, damaged organelles and 
eliminating intracellular pathogens. It is also upregulated under conditions of cellular 
stress like nutrient deprivation, providing an alternative source of intracellular 
building blocks and maintaining energy production for cell survival [104]. In cancer, 
this may contribute to tumor growth and therapeutic resistance [105].  
There are three main types of autophagy: macroautophagy, microautophagy, 
and chaperone-mediated autophagy. Microautophagy involves the direct uptake of 
cytosolic components by the lysosome itself through invagination of the lysosome 
membrane [106]. However, the role of microautophagy in higher eukaryotes remains 




Macroautophagy (hereafter referred to as autophagy) is characterized by the 
formation of double-membrane vesicles, known as autophagosomes, that engulfs 
cytoplasmic cargo. Autophagosomes then fuse with lysosomes, forming 
autolysosomes, where the cargo is then degraded by lysosomal enzymes. After 
degradation, lysosomal proteases and transporters export amino acids and other by-
products back out to the cytoplasm to be re-used for building macromolecules or for 
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metabolism [107]. Thus autophagy promotes energy efficiency through ATP 
generation and prevents cellular damage by removing non-functional proteins and 
organelles [106]. 
Autophagy has been widely studied in the yeast system and is regulated by 
many proteins like the autophagy-related genes (Atg) proteins. Many mammalian 
homologs of the Atg proteins have been found. Phagophore formation in mammalian 
systems is regulated by vesicular protein sorting 34 (Vps34), a class III phosphatidyl 
inositol 3-kinase (PI3K), and its binding partner Atg6/Beclin-1. The complex is 
essential for phagophore elongation and recruitment of other Atg proteins [108]. 
Other regulatory proteins also complex with Vps34 and Beclin-1 to either promote 
autophagy, such as UVRAG, BIF-1, Atg14L and Ambra [109, 110], or inhibit 
autophagy, such as Rubicon and Bcl-2 [111, 112]. The interaction of Bcl-2 and 
Beclin-1 on the regulation of autophagy has been well characterized. Beclin-1 
interacts with Bcl-2 via the BH3 domain, which disrupts its binding with Vsp34 and 
results in the inhibition of autophagy [112]. When cells undergo starvation, JNK1-
mediated phosphorylation of Bcl-2 releases Beclin-1 to interact with Vsp34 to 
promote autophagy [113]. 
In contrast to class III PI3K, class I PI3K has an inhibitory effect on 
autophagy. Class I PI3K generates phosphatidylinositol-3,4,5-triphosphate 
(PI(3,4,5)P3) and activates Akt, which in turn activates mammalian target of 
rapamycin (mTOR) [114]. mTOR downregulates autophagy by phosphorylating 
Atg13, preventing it from interacting with Ulk1 and inhibiting the formation of a 
trimeric complex required for autophagosome formation [115]. mTOR is a main 
regulator of autophagy. Under conditions of nutrient deprivation, hypoxia and low 
ATP levels, adenosine monophosphate kinase (AMPK) is activated, which represses 
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mTOR to initiate autophagy [116]. mTOR is also inhibited when there is reduced Akt 
activity in response to reduced growth factor receptor activity [117]. 
During the induction of autophagy, the microtubule-associated protein light 
chain 3 (LC3) is proteolytically cleaved by Atg4 to generate LC3-I. LC3-I is then 
activated and cleaved by Atg7 and Atg3 before conjugation to 
phosphatidylethanolamine (PE) to generate LC3-II [118]. The Atg5-Atg12-Atg16 
complex recruits LC3-II to the surfaces of the autophagosome to mediate hemifusion 
of membranes and selection of cargo for degradation [106]. The synthesis and 
processing of LC3 is increased during autophagy, making it a good indicator of 
autophagy levels in cells [119].  A summary of the signalling pathways regulating 
autophagy is illustrated in Figure 1.3 [106]. 
Autophagy can also be induced by unfolded protein response (UPR) under 
high ER stress. UPR is initiated when misfolded proteins accumulate beyond the 
processing capacity of the ER and serves as an alternative pathway for the removal of 
these proteins. In mammalian cells, double-stranded RNA-activated protein kinase 
(PKR)-like endoplasmic reticulum kinase (PERK), inositol requiring kinase 1 (IRE1) 
and increased cytosolic Ca2+ have been implicated as mediators of ER stress-induced 
autophagy [120]. It has been shown that polyglutamine repeats and other misfolded 
proteins that form aggregates in the cytoplasm induced ER stress [121], which 
induced autophagy, as observed by the upregulation of Atg12 and conversion of LC3-
I to LC3-II. It was demonstrated in murine cells that the PERK-elF2α signaling 
pathway is required for the induction of autophagy [122]. However, further work has 





Figure 1.3. Molecular circuitry and signalling pathways regulating autophagy. 
Autophagy is a complex self-degradative process that involves the following key 
steps: (a) control of phagophore formation by Beclin-1/VPS34 at the ER and other 
membranes in response to stress signalling pathways; (b) Atg5–Atg12 conjugation, 
interaction with Atg16L and multimerization at the phagophore; (c) LC3 processing 
and insertion into the extending phagophore membrane; (d) capture of random or 
selective targets for degradation, completion of the autophagosome accompanied by 
recycling of some LC3-II/ATG8 by ATG4, followed by; (e) fusion of the 
autophagosome with the lysosome and proteolytic degradation by lysosomal proteases 
of engulfed molecules.  
 
1.4.2 Chaperone-mediated autophagy 
Unlike microautophagy and macroautophagy, chaperone-mediated 
autophagy is a selective degradation process. Substrate proteins containing the 
KFERQ motif are recognized by the cytosolic heat shock cognate 70 (Hsc70) protein 
[123]. Hsc70 forms a complex with the protein substrate, heat shock protein 40 
(Hsp40) and heat shock protein 90 (Hsp90) with the aid of Hsc70-interacting protein 
(Hip) and Hsc70-Hsp90 organizing protein (Hop). Hsp40 activates the ATPase 
activity of Hsc70 and facilitates the binding of substrate proteins while Hsp90 
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prevents the aggregation of misfolded substrates [124]. This chaperone/substrate 
complex then binds to the lysosomal-associated membrane protein 2a (LAMP-2a) 
receptor on the lysosome membrane [124], where cytosolic Hsc70 helps to unfold the 
substrate protein [125]. Lysosomal Hsc70 is postulated to assist in the translocation of 
substrate protein into the lysosomal lumen to be degraded by lysosomal proteases 
[124].  
 
1.5 PI3K/Akt survival pathway 
The PI3K/Akt signaling pathway is essential for the regulation of multiple 
physiological processes such as cell cycle progression, transcription, translation, 
differentiation, apoptosis, motility and metabolism [126]. It is a major survival 
pathway deregulated in many cancers, contributing to cancer progression and 
resistance to therapy.  
PI3K is activated by growth factor receptor tyrosine kinases and G protein-
coupled receptors, and catalyzes the production of PIP3 at the cell membrane. PIP3 in 
turn recruits and activates a wide range of downstream targets, including the serine-
threonine kinase Akt. 3-phosphoinositide dependent protein kinase-1 (PDK1) binds to 
PIP3 through its pleckstrin homology (PH) domain and becomes activated. PDK1 
partially activates Akt by phosphorylating at T308. Further phosphorylation at S473 
results in the full activation of Akt [127]. Akt suppresses the apoptosis of cells 
induced by stimuli such as growth factor withdrawal, detachment of extracellular 
matrix components, UV irradiation, cell cycle discordance and activation of FAS 
signaling [128, 129]. 
The PI3K/Akt pathway regulates cell survival through several downstream 
targets. Akt downregulates either the expression or function of multiple proapoptotic 
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proteins which results in the enhancement of cell survival. Survival factors stimulate 
Akt to phosphorylate the proapoptotic Bcl-2 family member Bad, causing its 
sequestration from target proteins by 14-3-3 proteins [130]. Akt also inhibits the 
expression of Bim by phosphorylating the FOXO family of forkhead transcription 
factors, which are exported to the cytoplasm after binding 14-3-3 proteins [131]. In 
addition, it promotes the degradation of the tumour suppressor p53 by 
phosphorylating and activating its negative regulator Mdm2 [132]. 
The PI3K/Akt pathway contributes to the regulation of cell cycle progression 
together with the Ras/MAPK pathway. Akt phosphorylates and inhibits GSK3, thus 
preventing the degradation of cyclin D1 and Myc, allowing them to drive S phase 
entry [133, 134]. Akt-mediated phosphorylation of FOXO proteins also lifts the 
repression of cyclin D1 expression, as well as preventing the expression of cell cycle 
inhibitors [131]. Coordination between cell cycle progression and cell growth is 
essential for cell proliferation. Cell growth is largely regulated by protein synthesis 
and the high growth rate of tumour cells is likely due to the dysregulation of protein 
synthesis [135]. Akt activates mTOR in response to availability of nutrients and 
growth factors. mTOR plays a critical role in the regulation of translation initiation, 
ribosome biogenesis and cell growth [136]. Akt phosphorylates and inhibits tuberin, 
the product of the tuberous sclerosis complex-2 (TSC2), allowing Rheb-GTP to 
activate mTOR signalling [137]. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
1.6 Project hypothesis and objectives 
1.6.1 Current perspective in APL 
PML-RARα is widely thought to be involved in the leukemogenesis of APL. 
However, the exact mechanism by which this takes place remains unclear. It was 
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previously shown in our laboratory that the loss of function of N-CoR plays a role in 
the pathogenesis of APL. Further, PML-RARα has been demonstrated to bind 
aberrantly to N-CoR and induce its misfolded conformation, thus disrupting its 
tumour suppressive role in mediating the repression of self-renewal genes.  
Previous studies in APL mouse models have shown that transgenic mice 
developed an APL-like phenotype only when PML-RARα was specifically expressed 
in the early myeloid compartment [138, 139]. In almost all non-hematopoietic cells, 
PML-RARα demonstrated an anti-oncogenic effect [140] which suggests that the 
oncogenic potential of PML-RARα is specific to the promyelocytic compartment. In 
the promyelocytic compartment, its oncogenic potential is surprisingly linked to its 
inactivation through processing by aberrant proteases in promyelocytic cells [141] 
which indicates that the protein quality control mechanism UPR acts in the 
transformation of APL. 
When N-CoR is exogenously expressed with PML-RARα in human 
embryonic kidney 293 cells, PML-RARα binds to N-CoR and causes it to adopt a 
misfolded conformation and accumulate as insoluble aggregates in the ER, eventually 
leading to UPR-induced apoptosis [50].  However, APL cells are resistant to UPR-
induced apoptosis. Recently, Ng and colleagues reported that a glycoprotein 
endopeptidase OSGEP, found to be selectively expressed in APL cells, cleaves N-
CoR [142].  Thus, ER stress generated by misfolded proteins is kept within tolerable 
levels, allowing APL cells to escape cell death and continue proliferating. This 
protease processing of N-CoR forms the basis of a defense mechanism termed as ‘late’ 
cytoprotective UPR, which is activated when early cytoprotective UPR comprising of 
molecular chaperones and ERAD fail to neutralize the toxicity of misfolded proteins 
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[20]. A schematic diagram of the reglation of ER stress in APL cells is shown in 
Figure 1.4 [20]. 
Further, Ng and colleagues also found genistein and curcumin to exert potent 
anti-proliferative effects in many APL-derived cells. Genistein has been demonstrated 
to inhibit N-CoR misfolding in APL cells, possibly by inhibiting the phosphorylation-
dependent interaction between N-CoR and PML-RARα and subsequently dissociating 
N-CoR from PML-RARα. This allows N-CoR to exert its effect on the differentiation 
of APL cells [143]. On the contrary, curcumin exers its effects by promoting the 
accumulation of misfolded N-CoR through inhibition of the protease-mediated 
degradation and ERAD. The net effect is the induction of UPR-induced apoptosis of 
APL cells [144]. 
 
 
Figure 1.4. Representation of the regulation of ER stress and UPR in APL cells. 
(A) In non-APL cells, accumulation of misfolded PML–RAR/N-CoR protein in the 
ER stimulates ER stress, which ultimately leads to UPR-induced apoptosis. (B) In 
APL cells, however, toxicity associated with misfolded PML–RAR/N-CoR is 
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neutralized owing to their processing by APL cell-specific aberrant protease activity, 
resulting in a reduction of ER stress and eventual protection of APL cells from UPR-
induced apoptosis. The ultimate outcome of cytotoxic UPR will be antioncogenic, 
because it would result in elimination of PML–RAR-containing cells through 
apoptosis, whereas activation of cytoprotective UPR would allow the PML–RAR-
containing cells to remain viable and, along with the help of additional growth-
promoting stimuli, to proliferate.APL [20]: Acute promyelocytic leukemia; ER: 
Endoplasmic reticulum; N-CoR: Nuclear receptor corepressor; PML: Promyelocytic 
leukemia; RAR: Retinoic acid receptor; UPR: Unfolded protein response. 
 
1.6.2 Hypothesis and objectives 
Protein misfolding is implicated in many diseases, either through the resulting 
disappearence of a functional protein, or accumulation of insoluble aggregates. 
Accumulation of misfolded proteins is a hallmark of many neurodegenerative 
disorders such as Parkinson’s disease and Alzheimer’s disease. This can lead to 
altered neuronal connectivity, neuronal death, high ER stress and dysfunctional 
ERAD machinery [145, 146]. PML-RARα and N-CoR have been reported to be 
misfolded and implicated in the pathogenesis of APL. However, it appears that the 
degradation of the misfolded proteins, rather than their accumulation, leads to cancer 
progression. In APL cells, insoluble aggregates of misfolded N-CoR in the Golgi have 
been shown to be cleaved by the APL cell-specific OSGEP protease, thus relieving 
ER stress and allowing APL cells to escape UPR-linked apoptosis [142]. This 
suggests an important role of cytoprotective UPR in the pathogenesis of APL and a 
possible therapeutic target. In addition, preliminary data from our laboratory has 
shown that APL cells, NB4, are able to survive in serum-starved conditions while 
non-APL cells cannot survive under the same conditions. We hypothesize that APL 
cells utilize misfolded N-CoR, possibly acting through cytoprotective autophagy, to 




Figure 1.5. Proposed mechanism of the effects of misfolded N-CoR in APL and 
non-APL cells. 
 
Artemisinin is a natural plant product extracted from Artemisia annua. Its 
derivatives are now used in the standard therapy for falciparum malaria worldwide 
[80]. Artemisinin derivatives have also shown to possess anti-proliferative effects in 
many cancer cell lines including leukemia [82]. Hence, it is of interest to see if 
artemisinin derivatives can be used for cancer treatment. The artemisinin derivatives 
used in this study were provided by our collaborator Professor Haynes RK from Hong 
Kong Science and Technology University, Hong Kong. 
 
The main objectives are: 
1. To investigate if artemisinin derivatives may be a possible therapeutic drug for 
APL. 
2. To investigate the effect of artemisinin on misfolded N-CoR in APL. 
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
APL cell lines 
NB4, an all trans-retinoic acid (ATRA)-sensitive cell line and NB4-R1, the 
resistant variant, were generous gifts from Dr Homma Y (Department of Biosignal 
Research, Tokyo Metropolitan Institute of Gerontology, Japan) and Dr Lanotte M 
(INSERM U-301, Centre G. Hayem, Hôpital Saint-Louis, France) respectively. 
AP1060 was a kind gift from Dr Mori S (Cancer Science Institute, NUS, Singapore). 
 
Non-APL cell lines 
HL60, an acute myeloid leukemia (AML) cell line and K562, a chronic 
myelogenous leukemia (CML) cell line, were generous gifts from Dr Deng LW 
(Department of Biochemistry, YLL SoM, NUS, Singapore). HEK 293T cells were 




Different derivatives of artemisinin (Figure 2.1) were synthesized and given 
by our collaborator Prof Haynes RK (Hong Kong Science and Technology University, 
Hong Kong). The drugs were dissolved in dimethyl sulfoxide (DMSO) to a stock 




Figure 2.1. Chemical structures of synthesized artemisinin derivatives. 
 
MG132 
MG132 was obtained from Sigma Aldrich, USA and dissolved in DMSO to a 
stock concentration of 20 mM. Aliquots were stored at -20oC. 
 
2.1.3 Antibodies  
Primary antibodies 
Antibody Source Company Dilution used 
β-actin Mouse monoclonal TU-02, Santa Cruz 1:10 000 
Akt Rabbit polyclonal Cell Signaling 1:1000 
Beclin-1 Rabbit polyclonal Cell Signaling 1:1000 
Caspase 3 Rabbit polyclonal Cell Signaling 1:1000 
Caspase 4 Rabbit polyclonal Cell Signaling 1:1000 
Caspase 8 Mouse monoclonal 1C12, Cell Signaling 1:2000 
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Antibody Source Company Dilution used 
Caspase 9 Rabbit polyclonal Cell Signaling 1:1000 
Flag Mouse monoclonal F3165 clone M2, 
Sigma 
1:10 000 
HA Rabbit polyclonal Y11, Santa Cruz 1:1000 
LC3 Rabbit polyclonal NB100-2220,  
Novus Biologicals 
1:3000 
MTOR Rabbit polyclonal Cell Signaling 1:1000 
N-CoR Goat polyclonal C-20, Santa Cruz 1:500 
PARP Rabbit polyclonal Cell Signaling 1:1000 
Phospho-Akt Mouse monoclonal T308, Cell Signaling 1:1000 
Phospho-MTOR Rabbit polyclonal Ser2448,  
Cell Signaling 
1:1000 
PI3K Class III Rabbit polyclonal Cell signaling 1:1000 
RAR Rabbit polyclonal C20, Santa Cruz 1:1000 
Survivin Rabbit monoclonal Cell Signaling 1:1000 
 
Secondary antibodies 
Antibody Company Dilution 
Used 
Goat anti-mouse IgG (H+L), HRP 
conjugate 
Zymed Laboratories 1:10 000 
Goat anti-rabbit IgG (H+L), HRP 
conjugate 
Zymed Laboratories 1:10 000 
Mouse anti-goat IgG (H+L), HRP 
conjugate 









Semi-quantitative RT-PCR primers 





B2M F: 5’-ATCCAGCGTACTCCAAAGAT-3’ 
R: 5’-TTACATGTCTCGATCCCACT-3’ 
58 30 





2.2.1 Cell culture 
All leukemic cell lines were maintained in Rosewell Park Memorial Institute 
1640 (RPMI) medium (Invitrogen,USA) supplemented with 10% fetal bovine serum 
(FBS), purchased from Hyclone, UT. The human embryonic kidney (HEK) 293T cell 
line was maintained in Dulbecco’s modified Eagle’s medium (DMEM), purchased 
from Sigma, USA, supplemented with 10% FBS. All cells were cultured at 37oC in a 
humidified atmosphere with 5% CO2. 
 
2.2.2 Transfection 
293T cells were seeded at a density of 200x104 cells per 10-cm plate or 20x104 
cells per 6-well plate. Transfection was carried out 18-22 hrs after seeding. Fugene 6 
(Roche) was added to serum free DMEM and incubated for 5 mins at room 
temperature. DNA is then added to the mixture and incubated for another 15 mins at 
room temperature. The mixture was then slowly added dropwise to the cells. The cells 




Size of plate Fugene (µL) SF-DMEM (µL) Maximum DNA 
(µg) 
6-well 6 94 2 
10 cm 18 382 6 
 
2.2.3 Cell proliferation assay 
The cell proliferation assay was performed using the Cell Proliferation Kit I 
(MTT) (Roche) according to manufacturer’s instructions. Cells were seeded into 96-
well plates at 4000 cells/well in 100 µL culture medium with the respective drug 
concentrations. The cells were incubated at 37oC with 5% CO2 for 24-96 hrs. After 
the incubation period, 10 µL of the MTT labeling reagent was added to each well and 
incubated at 37oC for 4 hrs. Next, 100 µL of the solubilisation reagent was added to 
each well and allowed to stand in the incubator overnight for complete solubilisation 
of the purple formazan crystals. A microplate reader (Ultramark Microplate Imaging 
System, Biorad) was used to measure the spectrophometrical absorbance of the 
samples at a wavelength of 595 nm and a reference wavelength of 655 nm. 
 
2.2.4 Cell lysis for protein extraction 
Leukemic suspension cells were centrifuged at 200g for 5 mins and the pellet 
was washed twice with ice-cold 1x PBS. Harvesting of adherent cells was done by 
first removing the cell culture media and cells were washed with ice-cold 1x PBS. 
Cells were trypsinized and cell culture media was added to neutralize the trypsin. 
Cells were centrifuged at 200g for 5 mins and the pellet was washed twice with ice-
cold 1x PBS. 4 times the cell pellet volume of 1x SDS sample buffer (4x buffer-
250mM Tris-HCl (pH 6.8), 40% glycerol, 9.2% SDS, 0.01% bromophenol blue, 20% 
β-mercaptoethanol added fresh prior use; dilute with dH2O to get 1x) was added to 
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lyse the cells. The cells were sonicated two times on ice, 10 s each, with the sonicator 
(Branson Sonifier 150), output power of 5 W. The protein samples were then heated 
at 50oC for 10 mins and lysates were stored at -80oC. 
 
2.2.5 Western blotting 
Proteins in the cell lysates were seperated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE), using resolving gels of 6-15% and 5% stacking gel. 
Electrophoresis was carried out using 1x cold running buffer (25 mM Tris, 192 mM 
glycine, 0.1% SDS) at 4oC. After electrophoresis, the proteins on the gel was 
transferred onto a pre-wet PVDF membrane using a wet transelectroblotting system 
(Bio-Rad Inc., England) at a constant current of  75 mA for 2 hrs at 4oC in transfer 
buffer (48 mM Tris, 39 mM glycine, 0.037% SDS, 10% or 20% methanol). 10% 
methanol was used except when proteins of interest are below 30 kDa, where 20% 
methanol was used. After transfer, the membrane was blocked in PBS-T (PBS with 
0.1% Tween-20) containing 5% milk for at least 1 hr at room temperature. To detect 
phosphorylated proteins, the membrane was blocked in TBS-T (TBS with 0.1% 
Tween-20) containing 5% BSA. The membrane was then incubated with primary 
antibodies against the proteins of interest in the blocking buffers overnight at 4oC. 
After washing 3 times in PBS-T (or TBS-T, depending on blocking buffer) for 10 
mins each to remove excess antibodies, the membrane was incubated with the 
appropriate HRP-conjugated secondary antibodies in blocking buffer for 1 hr at room 
temperature. Excess antibodies were washed away by washing with PBS-T (or TBS-T) 
for 5 times, 10 mins each. The immunoreactive bands were detected by the Western 
Lightning Chemiluminescence Reagent Plus (Perkin Elmer) using an X-ray film, 
which was developed by a Konica Minolta SRX-101A film processor. 
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2.2.6 Polyacrylamide gels 
 Resolving gel Stacking 
gel 
Components 6% 8% 10% 12% 15% 5% 
Water (mL) 5.3 4.6 4.0 3.3 2.3 6.8 
30% acrylamide 
mix (mL) 
2.0 2.7 3.3 4.0 5.0 1.71 
1.5M Tris pH 8.8 
(mL) 
2.5 2.5 2.5 2.5 2.5 -- 
1M Tris pH 6.8 
(mL) 
-- -- -- -- -- 1.25 
10% SDS (mL) 0.1 0.1 0.1 0.1 0.1 0.1 
10% APS (mL) 0.1 0.1 0.1 0.1 0.1 0.1 
TEMED (µL) 8 6 4 4 4 10 
Total volume 
(mL) 
10 10 10 10 10 10 
 
2.2.7 Coomassie staining 
Cell lysates were loaded into gels and resolved by SDS-PAGE. After 
electrophoresis, the gel was stained with Coomassie Blue staining solution (0.25% 
Coomassie Blue, 10% acetic acid, 50% methanol) for 30 mins. The stained gel was 
then destained overnight with Coomassie destaining solution (10% acetic acid, 50% 
methanol). Coomassie gels were used to check the integrity of protein samples and as 







2.2.8 RNA extraction 
NB4 cells were pelleted by centrifugation at 200g for 5 mins at 4oC, then 
washed with ice cold 1x PBS. Purification of total RNA was carried out using the 
RNeasy Mini Kit (Qiagen, Germany) according to the manufacturer’s instructions. 
The cells were lysed in Buffer RLT (10 µl β-mercaptoethanol was added per 1 ml 
Buffer RLT before use) and homogenized using needle and syringe. 1 volume of 70% 
ethanol was added to the homogenized lysate and the sample was loaded onto the 
RNeasy Mini Spin column, followed by centrifugation at 8000 g for 15 s. The column 
was washed with Buffers RW1 and RPE. Lastly, purified RNA was eluted with 50 µl 
RNase-free water and its concentration was determined using Nanodrop 
Spectrophotometer ND-1000 (Thermo Fisher Scientific, USA).  
 
2.2.9 Reverse-transcription polymerase chain reaction (RT-PCR) 
First, 3 µg of the purified RNA template was used for cDNA synthesis using 
the RT-PCR System kit (Promega, USA). Reverse transcription was performed at 
42oC for 1 hr, and next at 65oC for 15 mins. Synthesis was terminated by incubation at 
95oC for 5 mins. Next, PCR amplification was carried out using the Thermal Cycler 
GeneAmp®PCR System 9600 (Applied Biosystems, USA). The annealing 
temperature and number of cycles were adjusted according to the primers used. PCR 








Table 2.1. Steps for PCR amplification 
 Steps Temperature (oC) Time 
1. Initialization 94 5 mins 
2. Denaturation 94 30 s 
3. Annealing 60 30 s 
4. Elongation 72 30 s 
 Cycle steps 2-4 for 30 times   
5. Final elongation 72 7 mins 
6. Final hold 4 ∞ 
 
 
2.2.10 Flow cytometry apoptosis assay  
The Annexin-V FITC Apoptosis Detection Kit I (BD Bioscience) was used for 
the detection of apoptosis by flow cytometry. The assay was carried out according to 
the manufacturer’s instructions. NB4 cells were seeded at 4x104 cells/ml in a 6-well 
plate and 1 uM of artemisinin derivative 11; henceforth referred to as GC011; was 
added for the required treatment time before harvesting.  The cells were washed twice 
with ice-cold 1x PBS and resuspended in 1x binding buffer to a concentration of 
10x106 cells/ml. 5 µl of Annexin V-FITC and 5 µl of propidium iodide (PI) were 
added to 100 µl of the resuspended cells (1x105 cells). The cells were vortexed gently 
and incubated for 15 mins at room temperature in the dark. 400 µl of 1x binding 
buffer was added the the cells and analyzed by flow cytometry. The untreated controls 
– unstained cells, cells stained with only Annexin V and cells stained with only PI 
were used to set up the compensation and quadrants. Flow cytometry analysis was 





2.2.11 Proteasome sensor assay 
20x104 293T cells were seeded in 6-well plates and each well was transfected 
with 2 µg of the proteasome sensor vector pZsProSensor-1 (BD Biosciences, 
Clonetech) as described in Section 2.2.2. The vector contains the mouse 
decarboxylase degradation domain (MODC d410) fused to the C-terminus of ZsGreen, 
a green fluosescent protein. MODC d410 fusion proteins are targeted to the 
proteasome and can be used to monitor proteasome activity. 24 hrs after transfection, 
cells were treated with 0 µM and 1 µM of GC011. 24 hrs after treatment, cells were 
viewed using the Nikon Eclipse TE2000-S microscope. 
 
2.2.12 Immunostaining and fluorescence microscopy 
20x104 293T cells were seeded in 6-well plates. Cells were co-transfected with 
1 µg of pACT-N-CoR-Flag and 1 µg of pACT-PML-RARα-HA as described in 
Section 2.2.2, and treated with varying concentrations of GC011 for 24 hrs. As the 
treated cells were found to detach after fixing, the cells were trypsinized and cytospun 
onto glass slides using the Shandon Cytospin 4 machine before fixing with 4% 
paraformaldehyde in PBS for 30 mins at 37oC. After washing 3 times, 5 mins with 
PBS, cells were permeabilized using 0.2% Triton X-100 in PBS for 5 mins on ice. 
The cells were washed 3 times with PBS and blocked with 5% BSA in PBS for 30 
mins at room temperature. After a brief rinse, the cells were incubated with anti-Flag 
and anti-HA primary antibodies at a dilution of 1:200 in 5% BSA for 3 hrs at room 
temperature. The cells were washed thrice again with PBS and incubated with 
appropriate Alexa Fluor secondary antibodies (Molecular Probes, Eugene, OR) at a 
dilution of 1:200 in 5% BSA for 1 hr at room temperature. After washing 3 times with 
PBS, the cells were stained with 150 nM of 4, 6-diamidino-2-phenylindole (DAPI) in 
35 
!
5% BSA for 5 mins, washed thrice with PBS and briefly rinsed with water. The slides 
were mounted with SlowFade® Gold anti-fade reagent (Molecular Probes, CA) and 
sealed with nail polish. The slides were viewed using the Nikon eclipse TE2000S 
microscope and images were captured and analyzed using Nikon ACT-2U imaging 
software. 
 
2.2.13 Measurement of internal ATP levels 
The ATP Bioluminescence Assay Kit HS II (Roche) was used to measure 
internal ATP levels of cells and the assay was carried out according to the 
manufacturer’s instructions. Cells were treated with 1 µM of GC011 for 0-24 hrs for 
the assay. 1x105 live cells were counted after staining with Tryphan blue, pelleted and 
washed twice with ice cold 1x PBS. The cells were then resuspended to a 
concentration of 1x105 cells/ml with dilution buffer. 300 µl of cell lysis buffer was 
added to 300 µl of the cell suspension and incubated for 5 mins at room temperature. 
The cell lysate was then centrifuged at 10 000 g for 1 min at 4oC and the supernatant 
was retained. The supernatant was diluted appropriately with dilution buffer. 100 µl 
of luciferase reagent was added to 50 µl of the diluted sample in a luciferase tube, 
mixed and luminescence was immediately measured using the Sirius Single Tube 
Luminometer (Berthold Detection System). Measurement was started after a 1 s delay 









Chapter 3: Results 
3.1 Artemisinin selectively inhibits the growth of APL but not non-APL cells 
Artemisinin has been shown to have anti-proliferative properties in various 
cancers but due to its poor solubility and bioavailability, many derivatives have since 
been developed. Our collaborator Professor Haynes RK has synthesized eight 
different artemisinin derivatives (Figure 2.1) and the primary objective is to identify if 
there is a derivative effective against APL induced by N-CoR misfolding. The 
therapeutic potential of these derivatives was tested in the APL cell line, NB4, via 
MTT cell proliferation assays. Using a range of concentrations between 0 µM to 25 
µM, the derivatives inhibited the proliferation of NB4 in a dose-dependent manner 
(Figures 3.1). Artemisinin derivatives 9 and 11 were found to be among the most 
potent (Figure 3.1F and H), while derivatives 1 and 6 did not show any anti-
proliferative effect (Figure 3.1A and E). Next, derivative 11 (henceforth referred to as 
GC011), shown to be the most effective, was selected to be further tested in two other 
APL cell lines, NB4-R1 and AP1060 (Figure 3.2A-C). GC011 also inhibited the 
proliferation of NB4-R1, a RA-resistant cell line. AP1060 is resistant to both RA and 
ATO [147]. Hence, GC011 is effective in both RA-sensitive and resistant cells. The 
effective concentration of GC011 in AP1060 is 1 µM, which is the highest among the 
three APL cell lines. The sensitivity of two other non-APL leukemic cell lines (HL60 
and K562) to the different artemisinin derivatives was also tested. Our findings 
suggest that artemisinin specifically inhibits the proliferation of APL cells but not 
non-APL cells (Figure 3.3A-B). Further, the selective sensitivity of NB4 is especially 
evident at a higher concentration of 5 µM.  
 























Figure 3.1. Artemisinin derivatives inhibit proliferation of NB4 cells. NB4 cells 
were treated with various concentrations of the different artemisinin derivatives for 
the durations indicated. Growth of the treated cells was measured by the MTT assay. 
(A and E) GC001 and GC006 failed to induce any growth inhibition. (B-D, F-H) 
GC002 and GC004 are effective at 5 µM; while the rest are effective at 1 µM. (F and 
H) GC009 and GC011 are the most effective in inhibiting NB4 cell proliferation. 










Figure 3.2. GC011 inhibits cell proliferation of RA-sensitive and RA-resistant 
APL cell lines. (A) RA-sensitive NB4, (B) RA-resistant NB4-R1 and (C) RA-
resistant AP1060 cells were treated with various concentrations of GC011 as stated 
for the durations as indicated. GC011 is equally effective in both NB4 and NB4-R1. 
The effective concentration in AP1060 is higher at 5 µM. Triplicates were measured 








Figure 3.3. Artemisinin derivatives selectively inhibit proliferation of APL cells. 
APL cells NB4 and non APL cells HL60 and K562 were treated with (A) 1 µM and 
(B) 5 µM of the various artemisinin derivatives for 72 hrs. Growth kinetics of the 
treated cells was measured by MTT assay. Growth inhibition was most prominent in 
NB4 cells, while K562 cells were the most resistant. Triplicates were measured for 





3.2 Artemisinin derivative, GC011,  promotes apoptosis of APL cells 
NB4 cells showed different morphological features characteristic of apoptosis 
such as membrane blebbing, cell shrinkage and cell fragmentation after exposure to 
GC011. We observed varying combinations and degrees of apoptotic features from 48 
to 72 hrs of treatment. To determine if there was an activation of apoptosis, Annexin-
V apoptosis assay using the flow cytometry was performed. Treatment with 1 µM 
GC011 induced an increase in the proportion of Annexin-V positive NB4 cells over 
time (Figure 3.4). Annexin-V positive cells have exposed phosphatidylserine which 
are indicative of apoptotic cells. GC011 also induced the activation of apoptotic 
markers. Cleavage of the initiator caspase 8, effector caspase 3, and PARP occurred 
after 24 hrs of treatment (Figure 3.5). Cleavage of caspase 9, on the other hand, 
occurred after 48 hrs of treatment. These results collectively suggest that GC011 
trigger apoptosis in APL cells. 
 
Figure 3.4. GC011 induces apoptosis in NB4 cells. NB4 cells were treated with 1 
µM GC011 for the durations as indicated. The population of Annexin V-positive cells 





Figure 3.5. GC011 activates the apoptotic pathway in NB4 cells. NB4 cells were 
treated with 1 µM GC011 for 24 and 48 hrs. Western blot analysis was carried out on 
the crude lysates using anti-caspase 8, anti-caspase 9, anti-caspase 3 and anti PARP 




3.3 Artemisinin derivative, GC011, promotes the degradation of misfolded N-
CoR and PML-RARα  
It has been shown previously that misfolded N-CoR and PML-RARα are 
cleaved in NB4 cells [141, 142]. Drugs such as AEBSF and curcumin were found to 
inhibit the growth of APL cells by inhibiting the degradation of misfolded N-CoR 
[142, 144]. This led to an accumulation of misfolded proteins and induction of UPR-
induced apoptosis. To investigate if artemisinin has a similar effect on the levels of N-
CoR in NB4, Western blot assay was done on NB4 cells treated with GC004, GC006 
and GC011. Based on the proliferation assay, GC011 exerted the greatest anti-
proliferative effect, while GC006 had no effect on cell proliferation (Figure 3.1 E and 
H). GC004, on the other hand, possessed a weaker anti-proliferative effect than 
GC011 (Figure 3.1 D). In this assay, GC006 was used as a control. We expected 
stabilization of full-length N-CoR in NB4 cells after treatment with GC011. However, 
we observed that N-CoR was instead further degraded after treatment. Full-length N-
CoR was clearly reduced and the cleaved band was completely abolished after 
treatment (Figure 3.6). This observation suggests that GC011 degrades both full-
length and cleaved N-CoR. The extent of degradation observed with each artemisinin 
derivative compound corresponded to the degrees of growth inhibition exerted. At 1 
µM concentration, GC006, which had no effect on the growth inhibition of NB4, 
failed to induce degradation of N-CoR while GC004 induced a slight decrease in the 
amount of full-length and cleaved N-CoR.  
Next, we wanted to ascertain if the decrease in N-CoR levels seen is due to 
GC011 and not by proteases inherent in APL cells. N-CoR was transfected together 
with PML-RARα to induce misfolding and then treated with GC011 in 293T cells. 
Treatment time was shortened to 24 hrs as 293T cells were more sensitive to the drug 
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GC011. N-CoR and PML-RARα proteins were found decreased in a dose-dependent 
manner after treatment (Figure 3.7). Imunofluorescence analysis was then employed 
to validate the result observed. Transfected N-CoR and PML-RARα was seen to co-
localize in the cytoplasm in 293T cells. Treatment with GC011 resulted in a decrease 
in frequency and intensity of N-CoR signal (Figure 3.8). These results collectively 
indicate that GC011inhibits the degradation of misfolded N-CoR.  
To test if GC011-induced degradation of N-CoR is selective only in APL cells, 
N-CoR levels in the non-APL cell line HL60 was compared with NB4 after treatment. 
After 48 hrs, N-CoR in NB4 was completely degraded while there was a marginal 
decrease in HL60 (Figure 3.9). This data suggests that GC011 is relatively selective 
for APL cells, as previously demonstrated by cell proliferation assays (Figure 3.3).  
 
Figure 3.6. GC011 enhanced the degradation of N-CoR and PML-RARα in NB4 
cells. NB4 cells were treated with 1 and 5 µM of the artemisinin derivatives as 
indicated for 48 hrs. Levels of N-CoR and PML-RARα were detected by western 
blotting using their respective antibodies. DMSO and GC006 treated cells were used 






Figure 3.7. GC011 induced the degradation of transfected N-CoR and PML-
RARα in 293T cells in a dose-dependent manner. 293T cells were transfected with 
N-CoR and PML-RARα plasmids and treated with various concentrations of GC011 
for 24 hrs. Western blot analysis of N-CoR and PML-RARα was done using anti-Flag 


























Figure 3.8. GC011 reduced the expression of transfected N-CoR and PML-RARα in the cytosol of 293T cells in a dose-dependent 
manner. 293T cells were transfected N-CoR and PML-RARα plasmids and treated with various concentrations of GC011 for 24 hrs. Cells were 
stained with anti-Flag to visualize N-CoR (green) and anti-HA to visualize PML-RARα (red). DNA was stained with DAPI (blue). Signals were 







Figure 3.9. GC011 induced a significant down-regulation of N-CoR in APL cells 
but not non-APL cells. APL (NB4) and non-APL (HL60) cells were treated with 1 
µM GC011 for 24 and 48 hrs. N-CoR in crude lysates was detected by Western blot 
analysis. 
 
3.4 Degradation of N-CoR by GC011 via the proteasome-dependent pathway 
in APL cells. 
3.4.1 GC011-induced N-CoR degradation is mediated via the proteasome 
pathway 
To investigate the mechanism of GC011-induced degradation of N-CoR, 
mRNA levels of N-CoR in treated and untreated cells was first measured via semi-
quantitative PCR. As shown in Figure 3.10, treatment with GC011 resulted in a 
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marginal decrease in the mRNA level of N-CoR. The continued presence of N-CoR 
mRNA could not account for the total degradation of N-CoR protein observed (Figure 
3.6) and this suggests that GC011 has a post-translational effect on N-CoR.  
One of the main routes for protein degradation in the cell is via the proteasome. 
It has been proposed that artemisinin induced the ubiquitination and proteasomal 
degradation of the androgen receptor in prostate cancer cells [77, 148]. Previous 
results from our laboratory also showed that N-CoR in the presence of PML-RARα 
becomes heavily ubiquitinated in NB4 cells [50]. To test if the decrease in N-CoR 
levels was a result of an increased proteasomal activity by GC011, the proteasome 
activity was determined using the proteasome sensor vector pZsProSensor-1 in 
GC011 treated 293T cells. The vector contains the ZsGreen fluorescent protein fused 
to mouse ornithine decarboxylase degradation domain (MODC d410), which targets it 
to the proteasome. Thus, the intensity of fluorescent signal is inversely proportional to 
proteasome activity. The number of cells with the green fluorescence signal and 
signal intensity decreases with increasing concentrations of GC011, indicating that 
GC011 enhances proteasomal activity in a dose-dependent manner (Figure 3.11).  
 
 
Figure 3.10. GC011 did not cause significant change to mRNA levels of N-CoR in 
NB4 cells. NB4 cells were treated with 1 µM GC011 for 24 and 48 hrs. Transcript 































Figure 3.11. GC011 enhanced the degradation of the proteasome sensor in 293T 
cells in a dose-dependent manner. 293T cells were transfected with the proteasome 
sensor and treated with various concentrations of GC011 for 24 hrs. Green 
fluorescence of the proteasome sensor was visualized. GC011 reduced the intensity of 
the signal, indicating an increased proteasome activity. 
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3.4.2 N-CoR is rescued by MG132 in GC011-treated APL cells 
To further verify if GC011-induced degradation of N-CoR is proteasome 
dependent, MG132 was used to determine if N-CoR can be stabilized. MG132 is a 
specific 26S proteasome inhibitor known to stabilize ubiquitinated proteins. NB4 cells 
were first treated with 1 µM GC011 for 24 hrs and varying concentrations of MG132 
was added 12 hrs before harvesting. Western blot analysis showed that both full 
length and cleaved N-CoR protein were stabilized with 10 µM MG132 (Figure 3.12). 
However, MG132 failed to prevent the down-regulation of PML-RARα. To confirm 
the dependence on the proteasome for N-CoR degradation, 293T cells were 
transfected with N-CoR and PML-RARα and treated with 2.5 µM GC011 and MG132 
in the same manner described for NB4 cells. Similar to the observation in NB4, 
MG132 treatment of transfected 293T cells resulted in stabilization of N-CoR protein 
in a dose-dependent manner. Maximum stabilization was obtained at 20 µM MG132. 
Likewise, there was no up-regulation of PML-RARα in 293T cells after MG132 




Figure 3.12. MG132 reversed GC011-induced N-CoR degradation in NB4 cells. 
NB4 cells were treated with 1 µM GC011 for 24 hrs. 12 hrs before harvest, various 
concentrations of MG132 was added. N-CoR and PML-RARα levels were detected 





Figure 3.13. MG132 reversed GC011-induced N-CoR degradation in 293T cells. 
293T cells were transfected with N-CoR and PML-RARα plasmids and treated with 
2.5 µM GC011 for 24 hrs. 12 hrs before harvest, various concentrations of MG132 
was added. N-CoR and PML-RARα levels were detected by Western blotting. Only 
N-CoR was stabilized by MG132. 
 
3.5 Autophagy is blocked by GC011 in APL cells 
3.5.1 Autophagy is activated in APL cells and contributes to cellular growth 
Cleavage of N-CoR in APL cells protects the cells from the cytotoxic effects 
of UPR and confers a survival and growth advantage [142]. We speculate that the 
protective arm of autophagy known as cytoprotective autophagy, may be a part of the 
proteolytic mechanism regulating this phenomenon. Autophagy is a cellular process 
activated in response to stress conditions such as nutrient deprivation and ER stress. 
In tumour cells, it has been reported that autophagy is induced to meet the high 
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metabolic demands required for increased cell proliferation [105]. When there is an 
accumulation of misfolded proteins in cells, UPR is activated and followed by 
cessation of protein synthesis, resulting in lower intracellular energy levels. Thus it is 
likely that in APL cells, degradation of misfolded N-CoR is a result of autophagy 
activation to compensate lower energy levels.  
To determine if autophagy is activated in NB4, LC3-II and LC3-I was 
measured in NB4, HL60 and K562 cells. LC3-I is processed to LC3-II and can be 
found on the membranes of autophagosomes during autophagy. Hence, an increased 
LC3-II/LC3-I ratio may indicate an increased activation of autophagy. We did not 
observe any significant difference between the levels of LC3-I and LC3-II in non-
APL cells, HL60 and K562. In these non-APL cells, basal level of autophagy, which 
is a common characteristic in all mammalian cells, was detected. However, in APL 
NB4 cells, there was a significantly higher level of LC3-II as compared to LC3-I 
(Figure 3.14). These results indicate that the level of autophagy is higher in APL cells 
compared to non-APL cells. 
To test the hypothesis that cytoprotective autophagy is activated in APL cells 
to compensate for the reduced intracellular energy levels arising from reduced protein 
synthesis, the ATP levels in NB4 cells were determined after bafilomycin A1 (BA-1) 
treatment. BA-1 blocks the fusion of autophagosomes and lysosomes during 
autophagy [149]. As shown in Figure 3.15, BA-1 treatment resulted in a dose-
dependent decrease of ATP levels in NB4 cells.  
Next, we seek to investigate if the activation of cytoprotective autophagy 
confers a survival advantage and contributes to the growth of APL cells under stress 
conditions. Both APL and non-APL cells were subjected to glucose starvation. When 
grown in glucose-free media, NB4 cells continued to grow, though at a slower rate 
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compared to growth in normal media (Figure 3.16A). In contrast, the growth of HL60 
and K562 ceased when grown in glucose-free conditions (Figure 3.16B). These 
results collectively suggest that activation of cytoprotective autophagy confers a pro-




Figure 3.14. LC3-II/LC3-I ratio is high in APL cells. Levels of LC3 in APL and 
non-APL cells were determined through Western blotting with anti-LC3 antibody. 
Cells were incubated with lysosomal protease inhibitors, E64D and pepstatin A for 5 
hrs to partially inhibit the degradation of LC3-II.  





Figure 3.15. BA-1 reduces the intracellular ATP level in NB4 cells in a dose-
dependent manner. NB4 cells were treated with various concentrations of BA-1 for 
48 hrs and intracellular ATP levels were measured by ATP assay.  









Figure 3.16. APL cells are resistant to glucose starvation-induced growth 
inhibition. APL (NB4) and non-APL (HL60 and K562) cells were grown under 
normal conditions (A) and under glucose-free conditions (B). All 3 cell lines grew at a 
similar rate when cultured in nutrient medium. When cultured in glucose-free 
medium, only NB4 continued to grow, but at a slower rate. Growth of non-APL cells 
was completely inhibited. 





3.5.2 GC011 blocks autophagy in NB4 cells 
Since degradation of misfolded N-CoR is speculated to provide intracellular 
energy through autophagy and support the survival of APL cells, it can be expected 
that further degradation of N-CoR by artemisinin can further activate autophagy and 
enhance cellular growth. However, we observed that artemisinin treatment induced 
growth inhibition and apoptosis of APL cells. To elucidate the mechanism of action 
exerted by GC011, its effect on autophagy in APL cells was examined. Western blot 
analysis was carried out on several autophagic markers such as class III PI3K, Beclin-
1 and LC3. These proteins are necessary for phagophore formation [108]. GC011 
treatment resulted in the down-regulation of all three proteins (Figure 3.17) and the 
down–regulation was more evident at 48 hrs. This finding suggests that GC011 
inhibits early autophagy in APL cells. 
 
Figure 3.17. GC011 inhibits autophagy in NB4 cells. NB4 cells were treated with 1 
µM GC011 for 24 and 48 hrs. Western blot analysis was carried out on crude lysates 
using anti-class III PI3K, anti-Beclin-1 and anti-LC3. 
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3.5.3 GC011-induced degradation of N-CoR is associated with a decrease in 
intracellular energy. 
It has been shown that inhibition of cytoprotective autophagy with BA-1 
results in the reduction of intracellular ATP levels in NB4 cells (Figure 3.15). As 
observed in the results above, GC011 also exerted an inhibitory effect on autophagy 
(Figure 3.17). Thus, we wanted to examine if GC011 could also have a similar effect 
as BA-1 on intracellular energy levels. First, N-CoR levels after various time-point 
treatments with GC011 were determined by Western blot analysis. Concurrently, the 
intracellular ATP levels at the various time-points were also measured. Consistent 
with previous results, treatment with GC011 led to the degradation of N-CoR. 
Prominent degradation could be seen at 18 hrs, with maximum degradation at 24 hrs 
(Figure 3.18A). Corresponding to the decreasing N-CoR levels, we observed 
decreasing intracellular ATP levels in NB4 cells with increasing exposure time to 
GC011 (Figure 3.18B). This finding suggests that the catabolism of misfolded N-CoR 











Figure 3.18. Reduction of intracellular ATP levels is associated with GC011-
induced N-CoR degradation in NB4 cells. NB4 cells were treated with 1 µM 
GC011 for the durations as indicated. (A) N-CoR levels were detected by Western 
blotting assay. (B) Intracellular ATP levels were detected by ATP assay. The decrease 







3.6 GC011 blocks autophagy via the PI3K/Akt survival pathway in APL cells 
The PI3K/Akt signaling pathway regulates several important cellular 
processes such as cell cycle progression, metabolism and apoptosis that are implicated 
in carcinogenesis [126]. Activation of this pathway results in uncontrolled cell growth 
and survival, conferring a growth advantage to tumour cells. mTOR, a protein 
downstream of Akt, is a main regulator of autophagy and protein synthesis [150]. A 
previous report by Ren et al. suggested that the PI3K pathway played an important 
role in the inhibition of autophagy and induced apoptosis in selenium-treated NB4 
cells [151]. Since treatment with GC011 has shown to promote apoptosis and inhibit 
autophagy, we determine to examine if GC011 has a regulatory effect on the 
PI3K/Akt pathway. As expected, we observed a down-regulation of the 
phosphorylation and activation of Akt and mTOR in NB4 cells after 48 hrs exposure 
to GC011 (Figure 3.19). 
The level of survivin after treatment was also determined. Survivin is a 
member of the inhibitor of apoptosis protein (IAP) family and is constitutively 
expressed in most cancers [152]. It can inhibit apoptosis by interfering with 
mitochondrial cytochrome c release and caspase-9 activity [153]. Since we have 
observed an activation of caspase-9 after treatment, we twanted to determine if there 
was a corresponding decrease in survivin. Indeed, GC011 also led to a down-
regulation of survivin protein (Figure 3.19). Together, these results suggest that the 
decreased survival of NB4 cells after GC011 treatment may be mediated by the 





Figure 3.19. GC011 inhibits the PI3K/Akt pathway in NB4 cells. NB4 cells were 
treated with 1 µM GC011 for 24 and 48 hrs. Western blot analysis was carried out on 






Chapter 4: Discussion 
4.1 Artemisinin shows promise as a therapeutic agent in APL 
Artemisinin, the active component of the Artemisia annua plant, has been used 
in traditional Chinese medicine for more than 2000 years to treat various illnesses 
[77]. Currently, artemisinin and its bioactive derivatives such as artemether, 
artesunate and dihydroartemisinin are recommended by the World Health 
Organization (WHO) for the treatment of multidrug-resistant strains of malaria [154].  
Of great interest, artemisinin derivatives exhibit potent anti-cancer activity in a 
variety of cancer cells. An analysis of 55 human cancer cell lines by the 
Developmental Program of the National Cancer Institute, USA showed that artesunate 
was most active against leukemic and colon cancer cell lines [82]. The mean IC50 in 
leukemic cell lines was reported to be about 1.11±0.56 µM, which was similar to the 
results from this study. In this study, treatment with 1 µM of GC011 for 72 hrs 
resulted in about 80% growth inhibition in NB4 and NB4-R1 cells, and approximately 
50% in AP1060 cells. This growth inhibition was seen more pronounced in APL cells 
than non-APL cell lines, demonstrating a higher selectivity for APL cells. APL cell 
lines exhibited response to GC011 at concentrations of 1 µM or lower, while growth 
inhibition was only observed in non-APL cells at 5 µM. Artemisinin can also mediate 
its anti-proliferative effect through many cellular pathways, such as activation of 
apoptosis, cell cycle arrest, and inhibition of angiogenesis and cell migration [77].  
Together, artemisinin and its derivatives are attractive therapeutic agents for 
cancer treatment. It is a natural product and is currently in use worldwide for the 
treatment of malaria. Thus, toxicity problems normally associated with developing 
drugs may be circumvented. Previous studies have also shown that the cytotoxic 
effects of artemisinin derivatives are selective for cancer cells and have much less 
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effect on neighbouring normal cells [155, 156]. A plausible explanation for the 
observation is that cancer cells contain relatively higher concentrations of iron, which 
cleave the endoperoxide bridge in artemisinin to release free radicals [157]. Taken 
together, the relatively higher selectivity of GC011 for APL cells may indicate that 
GC011 can be a potential therapeutic agent for APL. 
 
4.2 GC011 induces caspase-activated apoptotic pathways in APL 
Artemisinin may mediate apoptosis through activation of apoptotic regulators, 
upregulation of p38 mitogen-activated protein kinase (MAPK) and p53-mediated 
apoptosis and production of reactive oxygen species (ROS) [77]. Apoptotic assays 
carried out with Annexin V staining showed that GC011-treated APL cells undergo 
apoptosis. Consistent with reports in other cancers [158, 159], GC011 induced the 
activation of caspases-3 and -9. The caspase-9 apoptotic pathway mediates intrinsic 
apoptotic signals and is activated when there is increased cytochrome c release from 
the mitochondria [160]. An increase in cytochrome c release may be due to increased 
ER stress after treatment which activates the IRE1 pathway and Bim phosphorylation 
[161]. Stockwin et al. has reported that artemisinin dimmers upregulates the 
expression of ER stress markers in 2 different cancer cells [162]. Thus, it may be 
possible that GC011 can induce ER stress, which may be a factor for caspase-9 
activation in GC011-treated cells. Additionally, GC011 also induced the activation of 
caspase-8. It is possible that there is cross-talk between the caspase-8/Bid pathway 
and the caspase-9 mitochondrial pathway in GC011-induced apoptosis. Similar 
observations were also made by Gu et al. on aspirin-induced apoptosis in gastric 
cancer cells [163]. The Bcl-2 family member Bid provides a link between these two 
pathways. Bid is cleaved by caspase-8 and its truncated form tBid translocates to the 
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mitochondria where it acts together with Bax and Bak to induce cytochrome c release 
to activate the caspase-9 pathway [164]. However, further investigation is required to 
validate this theory. 
 
4.3 GC011 enhances N-CoR degradation through the proteasome pathway 
In APL cells, misfolded N-CoR is cleaved by a glycopeptidase, alleviating ER 
stress and this allows cells to escape UPR-induced apoptosis [142]. Previously, our 
laboratory discovered that therapeutic agents such as AEBSF and curcumin inhibited 
the degradation of N-CoR. Accumulation of misfolded proteins led to an in increase 
in ER stress levels and induction of UPR-induced apoptosis [142, 144]. In this study, 
we observed an increase in ER stress and apoptosis in GC011-treated NB4 cells 
which indicated that GC011 could also inhibit N-CoR degradation in a similar fashion. 
Unexpectedly, N-CoR and PML-RARα were found to be further degraded after 
treatment, suggesting a reactivation of a cellular protein quality control mechanism by 
artemisinin. Intracellular accumulation of misfolded proteins tends to inhibit the 
cellular protein quality control mechanism regulated by the proteasome. It is likely 
that artemisinin-induced degradation of residual misfolded N-CoR was triggered by 
the reactivation of cellular proteasomal activity originally inhibited by misfolded N-
CoR/PML-RAR proteins.  
As N-CoR was also found to be heavily ubiquitinated in NB4 cells [50], the 
investigation of proteasomal activities in GC011-treated NB4 cells was carried out. 
We observed that GC011 enhanced the degradation of the proteasome sensor 
expressed in 293T cells. However, MG132 treatment also restored the levels of N-
CoR degraded by GC011, suggesting that GC011 mediated the degradation of N-CoR 
through reactivating the proteasome pathway. On the contrary, MG132 treatment 
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failed to restore PML-RARα which was also degraded after GC011 treatment. This 
finding could indicate that PML-RARα could be degraded before MG132 was 
administered or proteasome degradation could not be the main degradation pathway. 
We hypothesize that GC011 may possibly enhance proteasome degradation via two 
modes of action: 1) directly enhancing proteasome activity, or 2) indirectly enhancing 
degradation through modification of N-CoR that renders it more susceptible to 
degradation.  
Proteasome activity can be regulated by proteins that bind the 19S regulatory 
particle (RP) and deliver ubiquitin-conjugated proteins to the proteasome, proteins 
that open the axial channel into the 20S core particle (CP), and ubiquitin ligases or 
deubiquitinating enzymes which modify proteasome-bound ubiquitin chains [165]. 
However, drug molecules which activate or enhance proteasome activity are rare and 
not well studied. PA28, PA200 and PA700 are three known types of cellular 
proteasome activators [166]. PA28 and PA200 bind the 20S CP to enforce channel 
gating in an ATP-independent manner to regulate degradation of non-ubiquitinated 
peptides [167, 168]. PA28 has been shown to enhance proteasome activity and 
improve the survival of Huntington’s disease model cells, where there is accumulation 
of intracellular ubiquitin-positive nuclear inclusion bodies of mutated huntingtin [169].  
PA700, the 19S RP, also binds the 20S CP to induce an open pore. But unlike PA28 
and PA200, PA700 regulates the degradation of ubiquitinated proteins in an ATP-
dependent manner [168]. Other reports suggest that oleuropein, a plant extract from 
Olea europea, fatty acids and SDS enhance proteasome activity by altering the 
conformation of the 20s CP to favor the open state [170, 171]. Presently, there has 
been no report on the involvement of artemisinin and direct proteasome activation 
which may possibly be examined in future. 
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Another possibility is that GC011 modifies N-CoR protein and renders it 
more susceptible to proteasome degradation. Proteins are tagged for proteasome 
degradation by post-translational modifications such as ubiquitination and 
posphorylation. Artemisinin derivatives have been demonstrated to enhance protein 
degradation through these modifications. Dihydroartemisinin accelerated the 
degradation of c-myc oncoprotein in tumour cells by enhancing the GSK 3β-mediated 
phosphorylation of c-myc [172]. In another report, artemisinin has been suggested to 
induce the MDM2-induced ubiquitination and proteasomal degradation of the 
androgen receptor protein in prostate cancer cells [77]. Proteasome activity has also 
been suggested to be enhanced by the inhibition of Usp14, a proteasome-associated 
deubiquitinating enzyme that can inhibit the degradation of ubiquitin-protein 
conjugates [165]. However, as N-CoR is already heavily ubiquitinated in NB4 cells, 
there may be a threshold to the effects of artemisinin in enhancing its ubiquitination. 
Hence, activating the proteasome activity directly may be a more possible mechanism. 
However, more work is needed to elucidate the mechanism of GC011 on regulating 
proteasome degradation.  
 
4.4 GC011 inhibits autophagy in NB4 cells 
It was shown in this study that GC011 inhibits autophagy in NB4 cells. In 
another study, Gozuacik et al. reported that autophagy may be linked to cell death 
[104]. Since apoptosis is activated after treatment with GC011, it may be expected 
that autophagy will be activated. However, there are two arms of autophagy: 
cytoprotective and cytotoxic [173]. As we have shown, autophagy is constitutively 
activated in NB4 cells. It is hypothesized that cytoprotective autophagy is activated in 
these cells. Accumulation of misfolded proteins like N-CoR and PML-RARα may 
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cause the UPS to be overwhelmed as it is unable to cope with the increased load [174]. 
Aggregated proteins may also clog the narrow barrels of the proteasomes and inhibit 
proteasome activity [175]. Autophagy has been suggested as an alternative 
mechanism to remove these aggregated proteins. Previous studies have shown that 
specific ubiquitin chains associated with protein aggregates recruit p62, which in turn 
binds to LC3-like molecules on autophagosomes to stimulate autophagy [175, 176]. 
N-CoR is misfolded and insoluble only in APL cells and not non-APL cells [142]. We 
observed that only NB4 APL cells were able to continue growing in starvation-
induced conditions. In addition, we have shown that the inhibition of autophagy 
reduces the intracellular ATP levels. Hence, we hypothesize that APL cells may 
utilize cytoprotective autophagy for the degradation of misfolded proteins to provide 
an alternative source of nutrients to maintain cellular growth. Thus, autophagic 
degradation of misfolded N-CoR not only abrogates the ER stress caused by 
accumulation of misfolded proteins but also confers a survival advantage to APL cells. 
 
4.5 GC011 inhibits the PI3K/Akt pathway in NB4 cells. 
We have found that GC011 inhibits mTOR and Akt phosphorylation in NB4 
cells. Although inhibition of mTOR is usually associated with the activation of 
autophagy [177, 178], we observed in this study that inhibition of mTOR and 
inhibition of autophagy occured after GC011 treatment. However, in situations where 
autophagy was activated, cell death also increased. It is possible that in these 
situations, it may be the cytotoxic arm of autophagy that is activated to induce cell 
death. However in NB4 cells, it is likely that autophagy plays a cytoprotective role 
suggesting that GC011 can possibly exert its effect by down-regulating cytoprotective 
autophagy to induce apoptosis. Apart from regulating autophagy, the Akt pathway 
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also regulates many other cellular processes such as cell growth, proliferation and 
survival [179]. Activation of the Akt pathway allows cancer cells to survive by 
inhibiting the proapoptotic signals and inducing survival signals, which may 
contribute to the malignant transformation of cells [180]. Thus, it is expected that 
GC011 will downregulate the Akt pathway to inhibit growth of APL cells. Cui et al. 
reported that the inhibition of PI3K, a protein upstream of Akt, significantly decreased 
autophagy levels but increased apoptosis levels in HeLa cells [181]. This was similar 
to what was seen in NB4 cells in this study where treatment with GC011 resulted in 
upregulation of apoptosis and downregulation of autophagy and the PI3K/Akt 
pathway.  
Akt is also known to elevate intracellular ATP levels via an increase in 
glycolysis and oxidative phosphorylation [182]. This is consistent with our 
observation that GC011 treatment results in a decrease in Akt activation and 
intracellular ATP levels along with N-CoR loss. 
 
4.6 Hypothesis model for the action of GC011 
Collectively, we hypothesize that accumulation of misfolded N-CoR and 
PML-RARα may inhibit proteasomal activity, which leads to the activation of 
autophagy. In NB4 cells, our results indicate that autophagy serves a cytoprotective 
function. First, it degrades the misfolded proteins to alleviate ER stress. Second, 
autophagy may break down the misfolded proteins to provide an alternative energy 
source for NB4 cell survival. We also hypothesize that GC011 induces the 
proteasomal degradation of misfolded N-CoR, possibly by either stimulating the 
proteasome activity directly or indirectly increasing degradation by acting on the post-
translational modification of N-CoR that renders it more susceptible for degradation. 
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Degradation of misfolded N-CoR leads to a decrease in intracellular ATP levels and 
exerts an anti-proliferation effect possibly because the extra energy source generated 
by the catabolism of misfolded N-CoR through autophagy to maintain the high 
requirements of tumour cell survival has now been removed. A model of the 








Figure 4.1. Schematic model of hypothesis in APL cells. (A) Proposed mechanism N-CoR degradation in APL cells. (B) Proposed mechanism 




4.7 Future work 
It has been established from previous studies that the accumulation of PML-
RARα and misfolded N-CoR contribute to the pathogenesis of APL. In this study, we 
observe that the synthetic artemisinin GC011 inhibits the proliferation of APL cells 
and is capable of enhancing the degradation of misfolded N-CoR possibly through 
increasing proteasome activity. However, the exact mechanism by which GC011 
stimulates this proteasome activity remains to be elucidated. It is crucial to determine 
the mechanism by which this drug exerts its effects. GC011 is an attractive potential 
therapeutic agent, possessing desirable properties which includes low toxicity and 
exerts its effects via mechanisms which are different from existing clinical drugs. 
Hence the next step would be to test the effects of this drug in APL mice models. APL 
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